Galephar Pharmaceutical Research
United States 73 employees Updated 9 July 2026
Galephar Pharmaceutical Research is a finished-dose manufacturer based in United States. It appears in 6 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), MINSA (CR) and Health Canada. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 5 June 2025 as NAI.
3
registered plants
2 with an FDA FEI number
6
filings
across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 5 June 2025 NAI US FDA
- 18 October 2024 VAI US FDA
- 1 November 2019 VAI US FDA
- 23 November 2015 VAI US FDA
- 11 June 2015 NAI US FDA
- 15 January 2013 NAI US FDA
- 7 May 2012 VAI US FDA
- 29 September 2011 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| JUNCOS, United States | Not on file |
| Juncos, United States | 3003068480 |
| Humacao, United States | 3008206797 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| ARCSA (EC) | 3 | None |
| MINSA (CR) | 2 | None |
| Health Canada | 1 | None |
| US FDA | None | 2 |
Comparing suppliers?
Choose your molecules and target markets. Galephar Pharmaceutical Research comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 5 June 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates